Table 1.

Baseline characteristics of the study groups at baseline, prior to vaccination

CharacteristicHealthy controls (n = 11)Nontreated mRCC controls (n = 7)Sunitinib-treated patients (n = 16)Sorafenib-treated patients (n = 6)P
Frequency(%)Frequency(%)Frequency(%)Frequency(%)
Sex
 Male54557113815830.201a
 Female6552293191170.201a
Age, y
 Mean655959640.214b 0.233c
 Range61–7347–6837–7651–74
Performance status
 0–111100710010061001.000a
 2
Nephrectomy
 Yes7100138161000.257a,d
 No319
 Not applicable11100
Prior immunotherapy
 Yes2294253500.5219a,d
 No5711275350
Mean leukocyte count (×109/l)6.36.74.86.10.0341b 0.042c
Mean absolute neutrophil count (×109/l)3.64.42.64.10.0143b 0.0196c
Mean absolute monocyte count (×109/l)0.40.50.30.30.0344c
Mean absolute lymphocyte count (×109/l)2.11.61.71.30.200b
Mean LDH (U/L)3985254610.1124b 0.164c
Influenza vaccination prior to 2008 (%)
 Yes65557110632330.969a
 No436229531117
 Unknown19116350

Abbreviation: LDH, lactate dehydrogenase.

  • aχ2 test.

  • bANOVA.

  • cKruskall Wallis.

  • dOnly tested between the patients groups.